naproxen has been researched along with rofecoxib in 125 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (rofecoxib) | Trials (rofecoxib) | Recent Studies (post-2010) (rofecoxib) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 1,914 | 307 | 163 |
| Protein | Taxonomy | naproxen (IC50) | rofecoxib (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.43 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 1.51 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.5 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.5 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.02 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 1.8 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3602 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.76 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.486 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.036 | |
| Sodium-dependent serotonin transporter | Macaca mulatta (Rhesus monkey) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 108 (86.40) | 29.6817 |
| 2010's | 15 (12.00) | 24.3611 |
| 2020's | 2 (1.60) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Jyothsna, A; Raghavendra, NM; Subrahmanyam, CV; Venkateswara Rao, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Sharma, SK; Wuest, F | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Arnout, J; Buntinx, A; Dallob, A; De Lepeleire, I; De Schepper, PJ; Depré, M; Ebel, DL; Gertz, BJ; Schwartz, JI; Tanaka, W; Van Hecken, A; Wong, PH; Wynants, K | 1 |
| Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Reicin, A; Schnitzer, TJ; Shapiro, D | 1 |
| Brown, J; Fricke, J; Kotey, P; Mehlisch, D; Morrison, BW; Yuan, W | 1 |
| Bourne, M; Brown, J; deAndrade, JR; Jove, M; Krupa, D; Reicin, A; Seidenberg, B; Walters, D | 1 |
| Atherton, CT; Calder, NA; Cote, J; Dallob, A; Garlick, NM; Gertz, BJ; Gottesdiener, K; Hawkey, CJ; Novak, S; Wight, NJ; Wong, P | 1 |
| Adelman, A | 1 |
| Delgado Fernández, M; Diez García, F; Zambrana García, JL | 1 |
| Gupta, S | 1 |
| Kellner, H | 1 |
| Browning, RA; Burgess, FW | 1 |
| Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR | 1 |
| Deray, G | 1 |
| Anderson, TJ; Mather, KJ; Raj, SR; Shewchuk, L; Verma, S | 1 |
| Hawkey, CJ; Jones, JI | 1 |
| Jain, NK; Kulkarni, SK; Singh, A | 1 |
| Wallace, JL | 1 |
| Chandra, A; Nair, MG; Schutzki, R; Seeram, NP | 1 |
| Vane, JR | 1 |
| Frankish, H | 1 |
| Miyake, K; Sakamoto, C | 1 |
| Clifford, LJ; Dewitt, DL; Nair, MG; Rana, J | 1 |
| Fidan, D; Frankish, R; Garner, S; Judd, M; Towheed, T; Tugwell, P; Wells, G | 2 |
| Fendrick, AM | 1 |
| Shaughnessy, AF | 1 |
| Jain, NK; Kulkarni, SK; Patil, CS; Singh, A | 1 |
| Brune, K; Gertz, BJ; Gottesdiener, KM; Holmes, GB; Kalyani, RN; Lasseter, KC; Laurenzi, M; Malice, MP; Redfern, KJ; Schwartz, JI; Vandormael, K | 1 |
| Bombardier, C; Brett, C; Davis, B; Hawkey, CJ; Laine, L; Reicin, A; Shapiro, D | 1 |
| DeTora, L; Geusens, PP; Kalla, A; Lau, CS; Sfikakis, P; Shingo, S; Tate, G; Truitt, K; Zhao, PL | 1 |
| Arbogast, PG; Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM | 1 |
| Amante, C; Chen, SL; Choon, D; Chow, CT; De Tora, L; Genti, G; Laurenzi, M; Lu, HS; Moan, A; Myllykangas-Luosujärvi, R; Pasero, G; Rodgers, DB; Sarembock, B; Vrijens, F; Zerbini, CA | 1 |
| Bombardier, C; Burgos-Vargas, R; Connors, LG; Hawkey, CJ; Laine, L; Reicin, A; Schnitzer, TJ; Yu, Q | 1 |
| Anderson, GM; Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Mamdani, M; Naglie, G; Rochon, P | 1 |
| Cmiel, A; Mejza, F; Szczeklik, A; Tuleja, E | 1 |
| Evans, J; Hawkey, CJ; Laine, L; Quan, H; Shingo, S; Simon, T | 1 |
| Aisen, PS; Grundman, M; Schafer, K; Thal, LJ; Thomas, R | 1 |
| Aisen, PS; Davis, KL; Farlow, MR; Grundman, M; Jin, S; Pfeiffer, E; Sano, M; Schafer, KA; Thal, LJ; Thomas, RG | 1 |
| Czap, A | 1 |
| Schiller, LR | 1 |
| Akyürek, C; Celik, C; Celik, JB; Reisli, R; Sarkilar, G; Tuncer, S | 1 |
| Robertson, M | 1 |
| Dixon, ME; Geba, GP; Johansson, G; Lisse, JR; Mollen, AJ; Perlman, M; Polis, AB; Schechtman, J; Shoemaker, JR; Skalky, CS | 1 |
| Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR | 1 |
| Harley, C; Wagner, S | 1 |
| Kurban, Y; Sahin, I; Saraçoğlu, F; Türkkani, B | 1 |
| Burian, M; Geisslinger, G | 1 |
| Mastalerz, L; Radziszewski, W; Setkowicz, M; Szczeklik, A; Zembowicz, A | 1 |
| Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ | 1 |
| Choi, HK; Kuntz, KM; Seeger, JD | 1 |
| Hanauer, LB | 1 |
| Jenkinson, ML | 1 |
| Rusche, JM | 1 |
| García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C | 1 |
| Jain, NK; Kulkarni, SK; Satyanarayana, PS; Singh, A | 1 |
| Chan, WS; Cheung, SH; Kwong, KS; Leung, SP | 1 |
| Fitzgerald, GA | 1 |
| Kulkarni, SK; Padi, SS | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N | 1 |
| Fidan, DD; Frankish, RR; Garner, SE; Judd, MG; Towheed, TE; Tugwell, P; Wells, G | 1 |
| Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL | 1 |
| Lucas, R; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Afshari, HM; Dahners, LE; Hanson, CA; Weinhold, PS | 1 |
| Arellano, FM | 1 |
| Chiou, CF; Ofman, JJ; Spiegel, BM | 1 |
| Andersson, LI; Brater, DC; Hedman, A; Huledal, G; Jonzon, B; Malmenäs, M; Odlind, B | 1 |
| Braunstein, N; Polis, A | 1 |
| Waxman, HA | 1 |
| De Boer, J; Fijnheer, R; Rothova, A; Ten Dam, N; van Kooij, B | 1 |
| McCarthy, DM | 1 |
| Frazier, KC | 1 |
| Dhir, A; Kulkarni, SK; Naidu, PS | 1 |
| Hee, A; Kivitz, AJ; Lipetz, RS; Sanders, N; Schnitzer, TJ | 1 |
| Antonioli, L; Blandizzi, C; Cei, S; Colucci, R; Del Tacca, M; Fornai, M; Gabriele, M; Graziani, F; Tonelli, M; Vassalle, C | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Bishnoi, M; Kulkarni, SK; Kumar, A; Patil, CS | 1 |
| Curfman, GD; Drazen, JM; Morrissey, S | 1 |
| Bombardier, C; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Laine, L; Schnitzer, TJ; Weaver, A | 1 |
| Dhir, A; Kulkarni, SK; Naidu, PS; Padi, SS | 1 |
| Reicin, A; Shapiro, D | 1 |
| Adelsberg, JV; Bolognese, JA; Cavanaugh, P; Chen, PY; Giannini, EH; Goodman, S; Kiss, MH; Lovell, DJ; Reicin, AS; Reiff, A; Zavaler, MF | 1 |
| Geisslinger, G; Tegeder, I | 1 |
| García Rodríguez, LA; Hernández-Díaz, S; Varas-Lorenzo, C | 1 |
| Cağici, CA; Calişkan, EE; Erkan, AN; Gencay, S; Ozlüoğlu, LN; Sener, M; Yavuz, H; Yilmaz, I; Yilmazer, C | 1 |
| Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J | 1 |
| Smith, R | 1 |
| Takahira, Y; Takeuchi, K; Tanaka, A; Yokota, A | 1 |
| Hewett, JA; Hewett, SJ; Silakova, JM | 1 |
| Henry, D; McGettigan, P | 1 |
| Häussler, B; Höer, A | 1 |
| Coulthard, P; Dean, AD; Gerry Cowan, C; Hawkesford, JE; Jeppsson, L; Lamey, PJ; Michael Hill, C; Seymour, RA; Sindet-Pederson, S; Svensson, O; Wickens, M | 1 |
| Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Nedjar, H; Rahme, E | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Day, CA; Jacob, RF; Mason, RP; Walter, MF | 1 |
| Geisslinger, G; Graff, J; Harder, S; Klinkhardt, U; Nüsing, RM; Seyberth, H; Skarke, C; Watzer, B | 1 |
| Andrade, SE; Boudreau, D; Brown, JS; Chan, KA; Davis, RL; Graham, D; Gunter, MJ; Gurwitz, JH; Herrinton, L; Kulldorff, M; Pettus, PT; Platt, R; Raebel, MA; Roblin, D; Smith, D | 1 |
| Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J | 1 |
| Banerjee, S; Brilakis, ES; Cryer, B; Cunningham, F; Harford, WV; Kazi, S; Kelly, KC; Little, BB; Warner, JJ; Weideman, RA | 1 |
| Jackson, G | 1 |
| Li, L | 1 |
| Finn, A; Oerther, SC | 1 |
| Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C | 1 |
| Kumar, A; Kumar, P; Kumari, B | 1 |
| Adrahtas, A; Bertucci, MC; Cheung, RY; Krum, H; Ma, JY; Wang, BH | 1 |
| Lynd, LD; Marra, CA; Najafzadeh, M; Sadatsafavi, M | 1 |
| Anwar, A; Anwar, IJ; Delafontaine, P | 1 |
| Matteson, EL; Thongprayoon, C; Ungprasert, P | 1 |
| Choi, HK; Dalal, DS; Dubreuil, M; Felson, DT; Lee, T; Lu, N; Zhang, Y | 1 |
| Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM | 1 |
| Gislason, G; Sondergaard, KB | 1 |
| Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
23 review(s) available for naproxen and rofecoxib
| Article | Year |
|---|---|
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Comorbidity; Cyclooxygenase 1; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lactones; Low Back Pain; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Risk; Sulfones; Thrombosis | 2001 |
Gastrointestinal safety of COX-2 specific inhibitors.
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Helicobacter Infections; Humans; Isoenzymes; Lactones; Membrane Proteins; Naproxen; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Sulfones | 2001 |
Selective cyclooxygenase-2 inhibitors: after the smoke has cleared.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Digestive System; Humans; Isoenzymes; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Sulfones | 2002 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Isoenzymes; Lactones; Membrane Proteins; Naproxen; Omeprazole; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Sulfones | 2002 |
Rofecoxib for the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Naproxen; Randomized Controlled Trials as Topic; Sulfones | 2002 |
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Costs; Female; Gastric Mucosa; Gastritis; Health Care Costs; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Naproxen; Probability; Prostaglandin-Endoperoxide Synthases; Risk Assessment; Sulfones | 2002 |
Rofecoxib for the treatment of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Humans; Lactones; Naproxen; Randomized Controlled Trials as Topic; Sulfones | 2002 |
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood Pressure; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Endothelium, Vascular; Epoprostenol; Humans; Isoenzymes; Lactones; Membrane Proteins; Models, Animal; Naproxen; Osteoarthritis; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Sulfones; Thrombosis; Thromboxanes | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
Rofecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; Naproxen; Randomized Controlled Trials as Topic; Sulfones | 2005 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal Diseases; Humans; Lactones; Lansoprazole; Naproxen; Omeprazole; Proton Pump Inhibitors; Pyrazoles; Rheumatology; Sulfonamides; Sulfones | 2005 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gastrointestinal Hemorrhage; Helicobacter Infections; Humans; Ibuprofen; Lactones; Naproxen; Peptic Ulcer; Risk Factors; Sulfones | 2002 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Heart Failure; Hemostasis; Humans; Hypertension; Lactones; Naproxen; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazoles; Sulfonamides; Sulfones | 2006 |
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Diclofenac; Dose-Response Relationship, Drug; Humans; Ibuprofen; Lactones; Myocardial Infarction; Naproxen; Risk Factors; Sulfones | 2006 |
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Lactones; Naproxen; Pyrazoles; Risk; Sulfonamides; Sulfones | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids.
Topics: Atherosclerosis; Cell Membrane; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Lipid Peroxidation; Lipoproteins, LDL; Naproxen; Prostaglandins I; Risk Factors; Sulfones; Thromboxanes | 2007 |
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Cyclooxygenase 1; Cyclooxygenase 2; Female; Follow-Up Studies; Homeostasis; Humans; Lactones; Male; Middle Aged; Naproxen; Prevalence; Randomized Controlled Trials as Topic; Risk Assessment; Sulfones | 2015 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprofen; Incidence; Indomethacin; Lactones; Meloxicam; Naproxen; Observational Studies as Topic; Odds Ratio; Piroxicam; Proportional Hazards Models; Stroke; Sulfones; Thiazines; Thiazoles | 2016 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Child, Preschool; Chronic Disease; Chronic Pain; Fenoprofen; Humans; Ibuprofen; Lactones; Meloxicam; Methoxsalen; Naproxen; Randomized Controlled Trials as Topic; Sulfones; Thiazines; Thiazoles | 2017 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Dementia; Hemorrhage; Humans; Incidence; Lactones; Middle Aged; Myocardial Infarction; Naproxen; Randomized Controlled Trials as Topic; Stroke; Sulfones | 2020 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
28 trial(s) available for naproxen and rofecoxib
| Article | Year |
|---|---|
Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
Topics: Adolescent; Adult; Bleeding Time; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Lipopolysaccharides; Meloxicam; Membrane Proteins; Middle Aged; Naproxen; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Sulfones; Thiazines; Thiazoles; Thromboxane B2 | 2000 |
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Duodenal Obstruction; Female; Gastric Outlet Obstruction; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Naproxen; Peptic Ulcer; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Sulfones | 2000 |
The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Molar, Third; Naproxen; Pain Measurement; Pain, Postoperative; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Statistics, Nonparametric; Sulfones; Survival Analysis; Time Factors; Tooth Extraction | 2000 |
Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain.
Topics: Adult; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; Male; Naproxen; Orthopedic Procedures; Pain, Postoperative; Sulfones | 2001 |
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.
Topics: Adult; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Gastric Mucosa; Humans; Isoenzymes; Lactones; Lipopolysaccharides; Male; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Sulfones; Thromboxane B2 | 2001 |
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Endoscopy, Gastrointestinal; Female; Humans; Lactones; Male; Middle Aged; Naproxen; Peptic Ulcer; Prospective Studies; Sulfones | 2001 |
Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation.
Topics: Acetylcholine; Adult; Blood Flow Velocity; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Forearm; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Naproxen; Nitroprusside; Plethysmography; Prostaglandin-Endoperoxide Synthases; Sulfones; Vasodilation; Vasodilator Agents | 2001 |
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Celecoxib; Creatinine; Cyclooxygenase Inhibitors; Diet; Double-Blind Method; Electrolytes; Female; Humans; Kidney; Lactones; Male; Middle Aged; Naproxen; Potassium; Pyrazoles; Sodium; Sodium Chloride, Dietary; Sulfonamides; Sulfones | 2002 |
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lactones; Middle Aged; Multivariate Analysis; Naproxen; Risk Factors; Sulfones; Treatment Outcome | 2002 |
A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Isoenzymes; Joints; Lactones; Male; Membrane Proteins; Middle Aged; Naproxen; Placebos; Prostaglandin-Endoperoxide Synthases; Sulfones; Treatment Outcome | 2002 |
Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.
Topics: Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Sulfones; Treatment Outcome | 2002 |
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Incidence; Isoenzymes; Lactones; Male; Membrane Proteins; Middle Aged; Naproxen; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Sulfones | 2003 |
Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Endothelium, Vascular; Fibrinolytic Agents; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Sulfones; Thrombin; Thromboxane B2 | 2003 |
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Lactones; Life Tables; Male; Middle Aged; Naproxen; Peptic Ulcer; Risk Factors; Sulfones | 2003 |
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Double-Blind Method; Female; Humans; Isoenzymes; Lactones; Male; Membrane Proteins; Naproxen; Neuropsychological Tests; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Regression Analysis; Sulfones; Treatment Outcome | 2003 |
A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy.
Topics: Adult; Analgesia; Cyclooxygenase Inhibitors; Dyspepsia; Female; Gastrointestinal Diseases; Heartburn; Humans; Hysterectomy; Lactones; Middle Aged; Morphine; Naproxen; Placebos; Postoperative Nausea and Vomiting; Premedication; Sulfones | 2003 |
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Prospective Studies; Sulfones | 2003 |
Dysmenorrhea treatment with a single daily dose of rofecoxib.
Topics: Administration, Oral; Adult; Analysis of Variance; Chi-Square Distribution; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Dysmenorrhea; Female; Follow-Up Studies; Humans; Lactones; Naproxen; Pain Measurement; Patient Satisfaction; Probability; Risk Assessment; Severity of Illness Index; Sulfones; Treatment Outcome | 2003 |
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Celecoxib; Computer Graphics; Cross-Over Studies; Cyclooxygenase Inhibitors; Cysteine; Double-Blind Method; Drug Eruptions; Female; Humans; Lactones; Leukotriene E4; Leukotrienes; Male; Middle Aged; Multivariate Analysis; Naproxen; Prospective Studies; Pyrazoles; Serine Endopeptidases; Skin; Sulfonamides; Sulfones; Treatment Outcome; Tryptases; Urticaria | 2003 |
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determination; Celecoxib; Cyclooxygenase Inhibitors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Probability; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Topics: Adult; Area Under Curve; Blood Pressure; Cyclooxygenase Inhibitors; Diet, Sodium-Restricted; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Iohexol; Lactones; Male; Naphthalenes; Naproxen; Nitric Oxide Donors; Potassium; Renin; Sodium; Sulfones | 2005 |
The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edema.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Female; Fluorescein Angiography; Humans; Lactones; Macular Edema; Male; Middle Aged; Naproxen; Pilot Projects; Retinal Vasculitis; Sulfones; Treatment Outcome; Visual Acuity | 2005 |
Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Naphthalenes; Naproxen; Osteoarthritis, Knee; Pain Measurement; Severity of Illness Index; Sulfones; Surveys and Questionnaires; Treatment Outcome | 2005 |
Cyclooxygenase-2 induction after oral surgery does not entirely account for analgesia after selective blockade of cyclooxygenase 2 in the preoperative period.
Topics: Actins; Adult; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Double-Blind Method; Female; Humans; Lactones; Male; Microdialysis; Naproxen; Oral Surgical Procedures; Pain, Postoperative; Prostaglandins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones | 2006 |
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Topics: Adolescent; Arthritis, Juvenile; Child; Child, Preschool; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Lactones; Longitudinal Studies; Male; Meloxicam; Naproxen; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
[Postoperative pain management in clinics of otolaryngology].
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics; Dipyrone; Etodolac; Female; Humans; Lactones; Male; Meloxicam; Middle Aged; Naproxen; Otorhinolaryngologic Surgical Procedures; Pain Measurement; Pain, Postoperative; Postoperative Period; Sulfones; Thiazines; Thiazoles; Treatment Outcome | 2006 |
Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lactones; Male; Mandible; Middle Aged; Molar, Third; Naphthalenes; Naproxen; Pain Measurement; Pain, Postoperative; Sulfones; Tooth Extraction; Treatment Outcome | 2006 |
Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.
Topics: Adult; Antigens, Neoplasm; Blood Platelets; Celecoxib; Cell Adhesion; Cyclic AMP; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Fibrinogen; Humans; Lactones; Leukocytes; Male; Naproxen; P-Selectin; Phospholipases A; Platelet Activation; Platelet Aggregation; Platelet Membrane Glycoprotein IIb; Prostaglandins; Pyrazoles; Reference Values; Sulfonamides; Sulfones; Thrombin; Thrombomodulin; Thromboxanes; Time Factors | 2007 |
74 other study(ies) available for naproxen and rofecoxib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Synthesis, pharmacological evaluation and docking studies of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs as COX-2 inhibitors.
Topics: Acetamides; Anti-Inflammatory Agents, Non-Steroidal; Benzothiazoles; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Discovery; Models, Molecular; Molecular Structure; Stereoisomerism | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; Humans; Ibuprofen; Microscopy, Confocal; Protein Binding; Pyrazoles; Rhodamines; Structure-Activity Relationship; Sulfonamides | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Is rofecoxib safer than naproxen?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Method; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Randomized Controlled Trials as Topic; Sulfones | 2001 |
Upper gastrointestinal toxicity of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Ethics, Medical; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Lactones; Middle Aged; Misoprostol; Naproxen; Proton Pump Inhibitors; Risk Factors; Sulfones | 2001 |
Upper gastrointestinal toxicity of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Humans; Kidney; Lactones; Naproxen; Sulfones | 2001 |
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Kidney; Kidney Diseases; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Risk Factors; Sulfonamides; Sulfones; Water-Electrolyte Imbalance | 2001 |
Lipopolysaccharide-mediated immobility in mice: reversal by cyclooxygenase enzyme inhibitors.
Topics: Animals; Antidepressive Agents, Tricyclic; Cyclooxygenase Inhibitors; Desipramine; Enterotoxins; Female; Fluoxetine; Lactones; Lipopolysaccharides; Male; Mice; Motor Activity; Naproxen; Reserpine; Selective Serotonin Reuptake Inhibitors; Sulfonamides; Sulfones; Swimming | 2001 |
Characterization, quantification, and bioactivities of anthocyanins in Cornus species.
Topics: Anthocyanins; Antioxidants; Celecoxib; Chromatography, High Pressure Liquid; Cornus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fruit; Ibuprofen; Isoenzymes; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Biomedicine. Back to an aspirin a day?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carotid Artery Injuries; Cell Division; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Epoprostenol; Homeostasis; Humans; Isoenzymes; Lactones; Membrane Proteins; Mice; Muscle, Smooth, Vascular; Myocardial Infarction; Naproxen; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfones; Thromboxane A2 | 2002 |
Why do COX-2 inhibitors increase risk of cardiovascular events?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Lactones; Membrane Proteins; Mice; Myocardial Infarction; Naproxen; Prostaglandin-Endoperoxide Synthases; Sulfones; Thromboxane A2 | 2002 |
Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench.
Topics: Aedes; Amides; Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Echinacea; Ibuprofen; Isoenzymes; Lactones; Lethal Dose 50; Naproxen; Phytotherapy; Plant Extracts; Plant Roots; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Right ballpark, wrong base: assessing safety of NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Peptic Ulcer; Sulfonamides; Sulfones | 2002 |
Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice.
Topics: Aging; Animals; Anxiety; Avoidance Learning; Cognition Disorders; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Gastrointestinal Diseases; Isoenzymes; Lactones; Lipopolysaccharides; Male; Membrane Proteins; Mice; Motor Activity; Muscarinic Antagonists; Naproxen; Postural Balance; Prostaglandin-Endoperoxide Synthases; Scopolamine; Sulfonamides; Sulfones | 2002 |
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coronary Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Medicaid; Membrane Proteins; Middle Aged; Naproxen; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; Tennessee | 2002 |
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Ontario; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones | 2003 |
NSAIDs and hypertension.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Naproxen; Randomized Controlled Trials as Topic; Risk Factors; Sulfones | 2003 |
Pass the tablet please.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Ginkgo biloba; Humans; Lactones; Memory; Naproxen; Phytotherapy; Randomized Controlled Trials as Topic; Sulfones; Tablets | 2003 |
Lower gastrointestinal complications of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Sulfones | 2003 |
Effect of NSAIDs on risk of Alzheimer's disease: confounding factors were not discussed.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Lactones; Naproxen; Randomized Controlled Trials as Topic; Risk Factors; Sulfones | 2003 |
[Selective COX 2 inhibitor rofecoxib. To "defy" the pain].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Lactones; Migraine Disorders; Naproxen; Pain; Pain, Postoperative; Placebos; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sulfones; Time Factors; Tooth Extraction; Toothache | 2003 |
Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Hypertension; Lactones; Male; Middle Aged; Naproxen; Osteoarthritis; Prospective Studies; Sulfones | 2003 |
Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Utilization Review; Female; Health Care Costs; Humans; Ibuprofen; Insurance Claim Review; Isoenzymes; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Naproxen; Patient Compliance; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Sulfonamides; Sulfones; United States | 2003 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Fibromyalgia; Follow-Up Studies; Humans; Ibuprofen; Isoenzymes; Lactones; Longitudinal Studies; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires | 2004 |
Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Decision Support Techniques; Female; Gastrointestinal Diseases; Humans; Lactones; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Naproxen; Quality of Life; Sulfones; Time Factors | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Osteoarthritis; Research; Sulfones | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Osteoarthritis; Sulfones | 2004 |
Tolerability of rofecoxib versus naproxen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Osteoarthritis; Sulfones | 2004 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case-Control Studies; Cohort Studies; Comorbidity; Coronary Disease; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Drug Synergism; Drug Utilization; Female; Follow-Up Studies; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Risk Factors; Spain; Sulfones | 2004 |
[Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lactones; Naproxen; Peptic Ulcer; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Risk; Sulfones | 2004 |
Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice.
Topics: Acetic Acid; Algorithms; Analgesics, Opioid; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Female; Isoenzymes; Lactones; Male; Membrane Proteins; Mice; Naloxone; Naproxen; Narcotic Antagonists; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Sulfones; Tramadol | 2004 |
Multiple comparisons with a control in families with both one-sided and two-sided hypotheses.
Topics: Aged; Anti-Inflammatory Agents; Celecoxib; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Lactones; Naproxen; Pyrazoles; Research Design; Sodium; Sulfonamides; Sulfones | 2004 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Hyperalgesia; Injections, Intraperitoneal; Lactones; Male; Naproxen; Neuralgia; Pain Measurement; Rats; Rats, Wistar; Sciatic Nerve; Sulfones | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2005 |
Cellular mechanisms of acetaminophen: role of cyclo-oxygenase.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cell Line; Cyclooxygenase Inhibitors; Diclofenac; Enzyme Activation; Humans; Ibuprofen; Indomethacin; Lactones; Lung; Naproxen; Oxidation-Reduction; Prostaglandin-Endoperoxide Synthases; Protein Biosynthesis; Sulfones; tert-Butylhydroperoxide; Transcription, Genetic | 2005 |
The effect of analgesic agents on the healing rat medial collateral ligament.
Topics: Acetaminophen; Administration, Oral; Analgesics; Animals; Butorphanol; Collateral Ligaments; Disease Models, Animal; Dose-Response Relationship, Drug; Lactones; Naproxen; Piroxicam; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Sulfones; Weight-Bearing; Wound Healing | 2005 |
The withdrawal of rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Death, Sudden, Cardiac; Drug Industry; Humans; Lactones; Naproxen; Pharmacoepidemiology; Product Surveillance, Postmarketing; Sulfones | 2005 |
Report of specific cardiovascular outcomes of the ADVANTAGE trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Naproxen; Osteoarthritis; Sulfones | 2005 |
The lessons of Vioxx--drug safety and sales.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Drug Evaluation; Drug Industry; Gastrointestinal Diseases; Humans; Lactones; Marketing; Myocardial Infarction; Naproxen; Scientific Misconduct; Sulfones; United States | 2005 |
The lessons of Vioxx.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Lactones; Marketing; Naproxen; Product Surveillance, Postmarketing; Sulfones; United States; United States Food and Drug Administration | 2005 |
Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Animals; Behavior, Animal; Brain; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Injections, Intraperitoneal; Lactones; Male; Mice; Naproxen; Neuroprotective Agents; Sulfonamides; Sulfones | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Lactones; Lipoxygenase Inhibitors; Mice; Naproxen; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Sulfonamides; Sulfones; Triterpenes | 2006 |
Expression of concern reaffirmed.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Research Design; Sulfones; Thromboembolism | 2006 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Sulfones | 2006 |
Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice.
Topics: Adrenal Glands; Analysis of Variance; Animals; Anxiety; Ascorbic Acid; Behavior, Animal; Biomarkers; Brain; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Glutathione; Hot Temperature; Hyperalgesia; Injections, Intraperitoneal; Lactones; Lipid Peroxidation; Male; Maze Learning; Mice; Motor Activity; Naproxen; Nitrites; Protective Agents; Restraint, Physical; Stress, Psychological; Sulfones | 2006 |
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Response to expression of concern regarding VIGOR study.
Topics: Arthritis, Rheumatoid; Data Interpretation, Statistical; Gastrointestinal Diseases; Humans; Lactones; Myocardial Infarction; Naproxen; Risk; Sulfones | 2006 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans | 2006 |
Lapses at the new England journal of medicine.
Topics: Boston; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Interprofessional Relations; Lactones; Myocardial Infarction; Naproxen; Periodicals as Topic; Randomized Controlled Trials as Topic; Sulfones | 2006 |
Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Disease Models, Animal; Enterobacteriaceae; Flurbiprofen; Gastrointestinal Motility; Indomethacin; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Lactones; Male; Naproxen; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfones; Time Factors; Up-Regulation | 2006 |
Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration.
Topics: Animals; Blotting, Western; Brain Edema; Cell Death; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Excitatory Amino Acid Agonists; Hippocampus; Lactones; Male; Mice; Microinjections; N-Methylaspartate; Naproxen; Nerve Degeneration; Neurons; Neuroprotective Agents; Sulfones | 2006 |
[Overestimated].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Myocardial Infarction; Naproxen; Odds Ratio; Risk; Risk Assessment; Stroke; Sulfones | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Male; Multivariate Analysis; Myocardial Infarction; Naproxen; Pyrazoles; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfonamides; Sulfones | 2006 |
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Hospitalization; Humans; Lactones; Male; Myocardial Infarction; Naproxen; Pyrazoles; Quebec; Retrospective Studies; Risk Assessment; Sulfonamides; Sulfones | 2007 |
New warnings about painkillers, new advice on what you can do.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Drug Interactions; Humans; Ibuprofen; Lactones; Naproxen; Sulfones | 2006 |
Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Celecoxib; Competitive Medical Plans; Health Maintenance Organizations; Humans; Insurance Claim Review; Lactones; Medical Records Systems, Computerized; Myocardial Infarction; Naproxen; Population Surveillance; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Retrospective Studies; Rhabdomyolysis; Sulfonamides; Sulfones; Time Factors; Treatment Outcome; United States | 2007 |
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States | 2008 |
The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Drug Utilization Review; Drugs, Generic; Etodolac; Humans; Incidence; Lactones; Male; Medical Records; Middle Aged; Myocardial Infarction; Naproxen; Prevalence; Prognosis; Pyrazoles; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Texas; Veterans | 2008 |
Seeds of doubt--ADVANTAGE no one.
Topics: Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Drug Industry; Gastrointestinal Diseases; Humans; Interprofessional Relations; Lactones; Naproxen; Sulfones | 2008 |
A conditional sequential sampling procedure for drug safety surveillance.
Topics: Aged; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Product Surveillance, Postmarketing; Risk; Sulfones | 2009 |
Can L(+)-lactate be used as a marker of experimentally induced inflammation in rats?
Topics: Animals; Arthritis, Experimental; Biomarkers; Carrageenan; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Edema; Freund's Adjuvant; Joints; Lactic Acid; Lactones; Male; Naproxen; Rats; Rats, Sprague-Dawley; Sulfones | 2010 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee | 2009 |
Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.
Topics: Animals; Anxiety; Catalase; Chronic Disease; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Glutathione; Isoxazoles; Lactones; Lipid Peroxidation; Male; Meloxicam; Memory; Mice; Motor Activity; Naproxen; Nitrites; Random Allocation; Stress, Psychological; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2010 |
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Celecoxib; Collagen; Cyclooxygenase 2 Inhibitors; Female; Fibroblasts; Fibrosis; Heart; Hep G2 Cells; Hepatocytes; Humans; Lactones; Male; Myocardium; Myocytes, Cardiac; Naproxen; Pyrazoles; Rats; Renin-Angiotensin System; Sulfonamides; Sulfones; Vasoconstrictor Agents | 2010 |
A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
Topics: Computer Simulation; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Lactones; Models, Biological; Monte Carlo Method; Naproxen; Quality-Adjusted Life Years; Sulfones | 2010 |
Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Logistic Models; Male; Meloxicam; Middle Aged; Naproxen; Odds Ratio; Osteoarthritis, Knee; Risk Factors; Sulfones; Thiazines; Thiazoles; Treatment Outcome; United Kingdom; Venous Thromboembolism | 2016 |
NSAIDs and cardiac arrest: Non-steroidal anti-inflammatory drug use is associated with increased risk of Out-of-hospital Cardiac Arrest: A nationwide Case-Time-Control study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Denmark; Humans; Ibuprofen; Lactones; Naproxen; Out-of-Hospital Cardiac Arrest; Risk Factors; Sulfones | 2017 |